Two decades of pharmacovigilance and clinical experience with highly purified rabies immunoglobulin F(ab')₂ fragments

References

• World Health Organization. Rabies - Bulletin - Europe. Rabies information system of the WHO collaboration centre for rabies surveillance and research. [cited 2016 Jan 14]. Available from: http://www.who-rabies-bulletin.org/about_rabies/classification.aspx
   Google Scholar
• Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002;2:327–343.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO expert consultation on rabies. Second report. Geneva: WHO; 2013. ( WHO Technical Report Series No. 982).
   Google Scholar
• Warrell MJ, Warrell DA. Rabies: the clinical features, management and prevention of the classic zoonosis. Clin Med. 2015;15:78–81.
   PubMed Web of Science ®Google Scholar
• Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9:e0003709.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rabies. 2016 [cited 2016 Jan 14]. Available from: http://www.who.int/rabies/en/
   Google Scholar
• World Health Organization. Rabies (Fact Sheet N°99). 2014 [cited 2016 Jan 14]. Available from: http://www.who.int/mediacentre/factsheets/fs099/en/
   Google Scholar
• Asian Rabies Expert Bureau. Asian rabies experts meet in Manila. 2009 [cited 2016 Sep 16]. Available from: http://www.areb.info/sites/default/files/files/Meetings/AREB_Press_Release_2009_for_website.pdf
   Google Scholar
• Global Alliance for Rabies Control. Global vaccine and immunization research forum: pre-exposure rabies vaccination (PreP) in children of endemic countries. 2014 [cited 2016 Sep 16]. Available from: http://www.who.int/immunization/research/forums_and_initiatives/02_Briggs_GVIRF14_Pre_exposure_Rabiesvacc.pdf
   Google Scholar
• Baltazard M, Bahmanyar M. [Field trials with rabies vaccine on persons bitten by rabid wolves]. Bull World Health Organ. 1955;13:747–772. French.
   PubMedGoogle Scholar
• World Health Organization. Human and dog rabies vaccines and immunoglobulins, Geneva. 2015 Oct 12−13 [cited 2016 Jan 14]. Available from: http://apps.who.int/iris/bitstream/10665/199176/1/WHO_HTM_NTD_NZD_201511_eng.pdf
   Google Scholar
• Jentes ES, Blanton JD, Johnson KJ, et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. J Travel Med. 2013;20:148–158.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rabies vaccines: WHO position paper. Wkly Epidemiol Rec. 2010;32:309–320.
   Google Scholar
• Lang J, Simanjuntak GH, Soerjosembodo S, et al. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Organ. 1998;76:491–495.
   PubMed Web of Science ®Google Scholar
• Lang J, Attanath P, Quiambao B, et al. Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. Acta Trop. 1998;70:317–333.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI – management and reporting of adverse reactions to medicinal products. EMA/873138/2011 Rev. London: EMA; 2011.
   Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I – pharmacovigilance systems and their quality systems. EMA/541760/2011. London: EMA; 2011.
   Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH E2A: clinical safety data management: definitions and standards for expedited reporting. 1994.
   Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH E2D: post-approval safety data management: definitions and standards for expedited reporting. 2003 Nov 12.
   Google Scholar
• International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use: ICH E2C (R2): periodic benefit-risk evaluation report (PBRER). 2003 Nov 12.
   Google Scholar
• Quiambao BP, Dytioco HZ, Dizon RM, et al. Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab’)(2) fragment rabies immunoglobulin (Favirab). PLoS Negl Trop Dis. 2008;2:e243.
   PubMed Web of Science ®Google Scholar
• Quiambao BP, Dy-Tioco HZ, Dizon RM, et al. Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines. Vaccine. 2009;27:7162–7166.
   PubMed Web of Science ®Google Scholar
• Quiambao B, Gepanayao C, Bermal N, et al. Immunogenicity and safety of three intradermal anti-rabies vaccination regimens using purified Vero cell rabies vaccine. APCRI J. 2008;X:15–19.
   Google Scholar
• Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25:5675–5684.
   PubMed Web of Science ®Google Scholar
• Wilde H, Khawplod P, Khamoltham T, et al. Rabies control in South and Southeast Asia. Vaccine. 2005;23:2284–2289.
   PubMed Web of Science ®Google Scholar
• Wilde H, Choomkasien P, Hemachudha T, et al. Failure of rabies postexposure treatment in Thailand. Vaccine. 1989;7:49–52.
   PubMed Web of Science ®Google Scholar
• Zhou W, Pool V, Iskander JK, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)–United States, 1991-2001. MMWR Surveill Summ. 2003;52:1–24.
   PubMedGoogle Scholar
• Hinrichsen VL, Kruskal B, O’Brien MA, et al. Using electronic medical records to enhance detection and reporting of vaccine adverse events. J Am Med Inform Assoc. 2007;14:731–735.
   PubMed Web of Science ®Google Scholar
• Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40–C44.
   PubMed Web of Science ®Google Scholar
• Sanofi Pasteur. Application for inclusion of Equine F(ab’)2 antivenoms in the WHO model list for essential medicines. [cited 2016 Jan 14]. Available from: http://archives.who.int/eml/expcom/expcom15/applications/newmed/equine/antivenoms.pdf
   Google Scholar
• Baldé MC, Chippaux J-P, Boiro MY, et al. [Clinical study of tolerance and effectiveness of a F(ab’)(2) polyvalent antienom for African snake bites in Kindia, Guinea]. Bull Soc Pathol Exot. 2012;105:157–161. French.
   PubMedGoogle Scholar
• De Haro L, Lang J, Bedry R, et al. [Snake bite by European vipers. A multicenter study of tolerance to Viperfav, a new intravenous antivenom]. Ann Fr Anesth Reanim. 1998;17:681–687. French.
   PubMed Web of Science ®Google Scholar
• Boels D, Hamel JF, Bretaudeau Deguigne M, et al. European viper envenomings: assessment of Viperfav™ and other symptomatic treatments. Clin Toxicol (Phila). 2012;50:189–196.
   PubMed Web of Science ®Google Scholar
• Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013;99:61–67.
   PubMed Web of Science ®Google Scholar
• Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012;30:7315–7320.
   PubMed Web of Science ®Google Scholar
• Serum Institute of India Ltd Pune India. A phase II/III, randomized, multi-centric, comparator-controlled study of the safety and neutralizing activity of a human monoclonal antibody to rabies (SII RMAb) administered in conjunction with rabies vaccine for post-exposure prophylaxis in patients following potential rabies exposure (CTRI number: CTRI/2012/05/002709). 2012 [cited 2016 Jul 16]. Available from: http://www.ctri.nic.in/Clinicaltrials/pmaindet2php?trialid=4191
   Google Scholar
• Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine. 2008;26:5922–5927.
   PubMed Web of Science ®Google Scholar
• Randomized phase II trial on safety and neutralizing activity of CL184 and rabies vaccine versus human rabies immune globulin (HRIG) and rabies vaccine in children and adolescents. [cited 2016 Jan 14]. Available from: http://clinicaltrials.gov/show/NCT00708084
   Google Scholar
• Crucell Holland BV. A randomized phase II trial to compare the safety and neutralizing activity of CL184 in combination with rabies vaccine vs. HRIG or placebo in combination with rabies vaccine in healthy adult subjects. 2008 [cited 2016 Jan 14]. Available from: https://clinicaltrialsgov/ct2/show/NCT00656097
   Google Scholar
• Crucell Holland BV. Rabies virus neutralizing activity and safety of CL184, a monoclonal antibody cocktail, in simulated rabies post-exposure prophylaxis in healthy adults. 2010 [cited 2016 Jan 14]. Available from: https://clinicaltrialsgov/ct2/show/NCT01228383
   Google Scholar
• Bharti OK, Madhusudana SN, Gaunta PL, et al. Local infiltration of rabies immunoglobulins without systemic intramuscular administration: an alternative cost effective approach for passive immunization against rabies. Hum Vaccin Immunother. 2016;12:837–842.
   PubMed Web of Science ®Google Scholar